

September 23, 2016

The logo features the word "DCAT" in blue, "TOP" in orange with an upward-pointing arrow, and "Industry NEWS" in blue.

***BUSY WEEK?** Here are the  
TOP INDUSTRY NEWS stories  
you might have missed, as  
selected by DCAT Editorial  
Director Patricia Van Arnum.*

The banner includes a starburst graphic with the text "DON'T MISS THIS INAUGURAL EVENT...", the DCAT logo, the event title "AFTER THE SHOW", the subtitle "A Member Company Networking Event", the location "BARCELONA 2016", and the date and time "WEDNESDAY OCTOBER 5TH • 6:00 PM – 8:30 PM • CASA LLOTJA DE MAR".

DCAT  
**AFTER** THE SHOW A Member Company Networking Event  
BARCELONA 2016  
WEDNESDAY OCTOBER 5TH • 6:00 PM – 8:30 PM • CASA LLOTJA DE MAR

### **1. GSK Names New CEO**

GlaxoSmithKline (GSK) has named Emma Walmsley, currently CEO of GSK's Consumer Healthcare Division, as GSK CEO Designate to succeed Andrew Witty as GSK CEO, when he retires in March 2017. The new CEO will inherit a company seeking to transform itself with a renewed pipeline and a strategy to include vaccines and consumer healthcare, in addition to its core focus on pharmaceuticals, as part of its growth plans. [Read More](#)

### **2. Bayer Stresses Pharma Post Mega-Merger with Monsanto**

Following its proposed \$66-billion acquisition of the agrochemical and seeds company, Monsanto, last week, Bayer management has reaffirmed its commitment to its pharmaceutical business with a plan for ambitious growth. [Read More](#)

### **3. Sanofi Defends US Patent for Top-Selling Product Lantus**

Sanofi has filed a patent-infringement suit against Merck Sharp & Dohme Corp. in a federal district court relating to its insulin products, Lantus (insulin glargine) and Lantus Solostar as Merck proceeds with a 505(b)2 new drug application with the FDA for an insulin glargine drug product. Lantus was Sanofi's top-selling product in 2015 with sales of EUR 6.4 billion (\$7.1 billion). [Read More](#)

### **4. Allergan to Acquire Tobira Therapeutics in \$1.7 Billion Deal**

Allergan has agreed to acquire Tobira Therapeutics, a clinical-stage biopharmaceutical company focused on non-alcoholic steatohepatitis and other liver diseases, for an upfront payment of \$28.35 per share and up to \$49.84 per share in contingent value rights for a total potential consideration of up to \$1.695 billion. [Read More](#)

### **5. Teva, Regeneron Form \$1.25 Billion Pain Therapy Pact**

Teva Pharmaceutical Industries has partnered with Regeneron Pharmaceuticals to develop and commercialize fasinumab, Regeneron's investigational nerve growth factor antibody in Phase III development for osteoarthritis pain and in Phase II development for chronic low-back pain. Teva will pay Regeneron \$250 million upfront and share equally in the global commercial value as well as

ongoing research and development costs of approximately \$1 billion. [Read More](#)

#### **6. Facebook Founder Commits \$3 Billion To Fight Disease**

Mark Zuckerberg, founder and chief executive officer of the social media website, Facebook, and his wife, Priscilla Chan, have pledged to invest \$3 billion over the next decade in an initiative for curing, preventing, or managing all disease. The couple has formed the Chan Zuckerberg Initiative to facilitate collaboration between engineers and scientists with plans that include a new \$600-million research biohub in California. [Read More](#)

#### **7. GE To Invest in New Modular BioManufacturing Campus**

GE plans to invest EUR 150 million (\$168 million) in a new biopharmaceutical manufacturing campus, GE BioPark Cork, in Ireland, which will feature the company's prefabricated, off-the-shelf biomanufacturing facilities, owned and run by GE customers. [Read More](#)

#### **8. WuXi Biologics Opens New Biomanufacturing Facility in China**

WuXi Biologics, a WuXi AppTec company, has opened a new commercial-scale cGMP biologics perfusion manufacturing facility in Wuxi City, China. The company announced plans to build the facility in April 2015 and invested \$150 million. [Read More](#)

#### **9. Teva, Intel in Pact for Digital Therapy**

In another example of "moving beyond the pill," Teva Pharmaceutical Industries has formed a collaboration with Intel to develop a wearable device and machine-learning platform for use in therapies to treat Huntington disease. Teva, working in collaboration with Intel, will deploy this technology platform within an ongoing Phase II study. [Read More](#)

#### **10. GSK Addresses Global Health Challenges; Plans to Create a GSK-Led Biopreparedness Organization**

GlaxoSmithKline (GSK) has announced it will set out a series of steps to further address emerging global health challenges as the UN General Assembly took place in New York this week. GSK plans to create a Biopreparedness Organization within GSK as a dedicated, permanent organization operating on a no-profit, no-loss basis that will focus on designing and developing new vaccines against potential public health threats. [Read More](#)

#### **\*\*Upcoming DCAT Event\*\***

##### **DCAT After the Show**

Don't miss DCAT's inaugural networking event following CPhI Worldwide in Barcelona on Wednesday, October 5th from 6:00 PM to 8:30 PM at the beautiful Casa Llotja de Mar. Located just steps away from the Gothic Quarter and Port of Barcelona, this event offers the perfect opportunity to utilize that time between the tradeshow and your late-night dinner plans to catch up with colleagues and establish valuable industry connections.

Registration for this event is now open. The reception is \$79.00 USD per person, and includes food and beverage, and transportation from the show to Casa Llotja de Mar, compliments of ACIC Fine Chemicals, Inc. Further event information and available branding opportunities may be found [here](#).

*The DCAT organization is happy to provide this service to its members each Friday.  
Have a great weekend!*

#### **About Top Industry News**

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691  
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599  
[www.dcat.org](http://www.dcat.org)

Drug, Chemical, & Associated Technologies Association, One Union Street,  
Suite 208, Robbinsville, NJ 08691

[SafeUnsubscribe™ {recipient's email}](#)

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by [dcatnews@dcat.org](mailto:dcatnews@dcat.org)